Longeveron (LGVN) Revenue (2020 - 2026)
Longeveron (LGVN) recorded quarterly Revenue of $398000.0 in Q1 2026, up 9.04% quarter-over-quarter from $365000.0 in Q4 2025, and up 4.46% on a YoY basis from $381000.0 in Q1 2025.
Longeveron (LGVN) Revenue (2020 - 2026) Analysis & Trends
Longeveron's Revenue history runs 7 years deep, the most recent figure standing at $398000.0 for Q1 2026.
- In Q1 2026, Revenue rose 4.46% year-over-year to $398000.0; the TTM figure through Mar 2026 stood at $1.2 million (down 45.35% YoY), while the FY2025 annual figure was $1.2 million, down 49.87% from the prior year.
- Revenue was $398000.0 for Q1 2026 at Longeveron, up from $365000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $773000.0 in Q3 2024 to a low of $63000.0 in Q4 2023.
- Historically, Revenue has averaged $338529.4 across 5 years, with a median of $365000.0 in 2025.
- The sharpest annual moves came in 2024 and 2025: Revenue jumped 857.14% in 2024, then slumped 82.28% in 2025.
- A 5-year view of Revenue shows it stood at $121000.0 in 2022, then plunged by 47.93% to $63000.0 in 2023, then surged by 857.14% to $603000.0 in 2024, then sank by 39.47% to $365000.0 in 2025, then advanced by 9.04% to $398000.0 in 2026.
- The last three Revenue figures came in at $398000.0 (Q1 2026), $365000.0 (Q4 2025), and $137000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 5.21 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 306.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.99 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 398,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 398,000.00 |
| Dec 31, 2025 | 365,000.00 |
| Sep 30, 2025 | 137,000.00 |
| Jun 30, 2025 | 316,000.00 |
| Mar 31, 2025 | 381,000.00 |
| Dec 31, 2024 | 603,000.00 |
| Sep 30, 2024 | 773,000.00 |
| Jun 30, 2024 | 468,000.00 |
| Mar 31, 2024 | 548,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Sep 30, 2023 | 150,000.00 |
| Jun 30, 2023 | 217,000.00 |
| Mar 31, 2023 | 279,000.00 |
| Dec 31, 2022 | 121,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 466,000.00 |
| Mar 31, 2022 | 370,000.00 |
| Dec 31, 2021 | 209,000.00 |
| Sep 30, 2021 | 232,000.00 |
| Jun 30, 2021 | 489,000.00 |